2012-02-11 04:05:50 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Rectal Cancer - Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Rectal Cancer - Pipeline Review, H1 2012', provides an overview of the Rectal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Rectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rectal Cancer. 'Rectal Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability

and relevance of data for the indicated disease.


Full Report Details at
- www.fastmr.com/prod/330119_rectal_cancer_pipeline_review_h1_2012 ..


Scope

* A snapshot of the global therapeutic scenario for Rectal Cancer.
* A review of the Rectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Rectal Cancer pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Rectal Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Rectal Cancer pipeline depth and focus of Rectal Cancer therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rectal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Rectal Cancer
Rectal Cancer Therapeutics under Development by Companies
Rectal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Rectal Cancer Therapeutics - Products under Development by Companies
Rectal Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Rectal Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
Sanofi-Aventis
Eli Lilly and Company
Celltrion, Inc.
Corporacion Parc Tauli
Globeimmune, Inc.
Isofol Medical AB
Rectal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Rapamycin + Radiation Therapy - Drug Profile
Celecoxib - Drug Profile
Capecitabine For Rectal Cancer - Drug Profile
Bevacizumab + Erlotinib + Capecitabine + Radiation Therapy - Drug Profile
Capecitabine + Sorafenib + Radiation Therapy - Drug Profile
Capecitabine + Panitumumab + Radiation Therapy - Drug Profile
Bevacizumab + Erlotinib + 5-Fluorouracil + External Beam Radiation Therapy - Drug Profile
Oxaliplatin + Capecitabine + Intensity-modified Radiation Therapy - Drug Profile
Celecoxib + Radiation Therapy - Drug Profile
Capecitabine + Oxaliplatin + Bevacizumab + Radiation Therapy - Drug Profile
Celebrex + 5-FU + Radiation Therapy - Drug Profile
5-Fluorouracil + Oxaliplatin + Calcium Folinate + Radiation Therapy - Drug Profile
Capecitabine + Radiation Therapy - Drug Profile
Erbitux + Capecitabine + Radiation Therapy - Drug Profile
Oxaliplatin + Capecitabine + Cetuximab + Radiation Therapy - Drug Profile
HLA-A*2402-Restricted RNF43-TOMM34-VEGFR1-VEGFR2 Multipeptide Vaccine + Tegafur + Uracil + Folinate - Drug Profile
Capecitabine + Oxaliplatin + Radiation Therapy - Drug Profile
5-Fluorouracil + Avastin + Radiation Therapy + Oxaliplatin + Leucovorin - Drug Profile
Oxaliplatin + 5-FU + Leucovorin + Radiation Therapy - Drug Profile
IMC-A12 + Irinotecan + Cetuximab - Drug Profile
XELOX + Radiotherapy - Drug Profile
Bevacizumab + Capecitabine + Radiotherapy - Drug Profile
Panitumumab + CAPOX - Drug Profile
Capecitabine + Bevacizumab + Radiation Therapy - Drug Profile
Cetuximab - Drug Profile
Celebrex + Xeloda + Radiation Therapy - Drug Profile
Fluorouracil + Leucovorin + Oxaliplatin - Drug Profile
FOLFIRI - Drug Profile
Eloxatin + Xeloda + Radiation Therapy - Drug Profile
5-Fluorouracil + Folinic Acid - Drug Profile
Bevacizumab + Xeloda + Radiotherapy - Drug Profile
Fluorouracil + Leucovorin Calcium + Radiation Therapy - Drug Profile
Eloxatin + Xeloda + RadiationTherapy - Drug Profile
Cetuximab + 5-Fluorouracil + Radiation Therapy - Drug Profile
Oxaliplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=330119&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.